SCHEMBL1006497

SCHEMBL1006497

N#Cc1nc(Cl)ccc1Br

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.33
ALDH1A1 P00352 2/20 0.33
MBOAT4 Q96T53 1/20 0.33
POLB P06746 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
USP8 P40818 2/20 0.32
USP7 Q93009 2/20 0.32
USP47 Q96K76 1/20 0.32
ERBB2 P04626 2/20 0.32
SLC1A5 Q15758 1/20 0.30
NPC1 O15118 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP3A4 P08684 1/20 0.30
GAA P10253 1/20 0.30
CYP2D6 P10635 1/20 0.30
CYP2C9 P11712 1/20 0.30
HPGD P15428 1/20 0.30
ALOX15 P16050 1/20 0.30
ALOX12 P18054 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL913934 0.78 BACE1 (0.39) KDM4EMBOAT4USP8ERBB2NPC1
SCHEMBL30867996 0.78 BACE1 (0.39) KDM4EMBOAT4USP8ERBB2NPC1
SCHEMBL19715553 0.77 MBOAT4 (0.35) MBOAT4USP8USP7USP47ERBB2
SCHEMBL30450356 0.77 KDM4E (0.39) KDM4EALDH1A1MBOAT4POLBUSP8
SCHEMBL7108696 0.77 KDM4E (0.39) KDM4EALDH1A1MBOAT4POLBUSP8
SCHEMBL2708620 0.76 RPS6KA5 (0.39) KDM4EALDH1A1MBOAT4POLBL3MBTL1
Ammonia Solution, Strong SCHEMBL28870434 0.76 KDM4E (0.38) KDM4EALDH1A1MBOAT4POLBUSP8
SCHEMBL13291167 0.74 ALDH1A1 (0.33) KDM4EALDH1A1POLBUSP8USP7
SCHEMBL3399707 0.74 KHK (0.36) KDM4EALDH1A1MBOAT4POLBL3MBTL1
SCHEMBL12806576 0.74 MEN1 (0.35) MBOAT4USP7USP47ERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112500337-B Synthetic method of 3-bromo-6-chloropyridine formamide 苏州康润医药有限公司 2022-04-12 CN claimed
CN-112500337-A Synthetic method of 3-bromo-6-chloropyridine formamide 苏州康润医药有限公司 2021-03-16 CN claimed
CN-211216628-U Reaction device for processing 3-bromo-6-chloropyridine-2-carbonitrile 南京道尔顿化学技术有限公司 2020-08-11 CN claimed
CN-110404495-A A kind of reaction unit for the bromo- 6- chloropyridine -2- formonitrile HCN processing of 3- NANJING DAOERDUN CHEMICAL TECH CO LTD 2019-11-05 CN claimed
WO-2025021182-A1 CYP11A1 INHIBITORS ACERAND THERAPEUTICS (HONG KONG) LIMITED (CN) 2025-01-30 WO disclosed
WO-2024183806-A1 COMPOUNDS, PREPARATION METHODS AND USES THEREOF InventisBio Co., Ltd. (CN) 2024-09-12 WO disclosed
US-20240285611-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBVIE INC. (US) 2024-08-29 US disclosed
US-20230365526-A1 PYRIDAZINE DERIVATIVES FOR MODULATING NUCLEIC ACID SPLICING REMIX THERAPEUTICS INC (US) 2023-11-16 US disclosed
US-11786519-B2 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases ABBVIE INC. (US) 2023-10-17 US disclosed
WO-2023110843-A1 HETEROBICYCLIC DERIVATIVES AS ITK INHIBITORS ALMIRALL, S.A. (ES) 2023-06-22 WO disclosed
US-RE49446-E1 Oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-03-07 US disclosed
EP-4110771-A1 PYRIDAZINE DERIVATIVES FOR MODULATING NUCLEIC ACID SPLICING Remix Therapeutics Inc. (US) 2023-01-04 EP disclosed
WO-2011084549-A1 HOMOGENEOUS SUSPENSION OF IMMUNOPOTENTIATING COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2011-07-14 WO disclosed
CN-102015651-A Compounds and compositions as TLR activity modulators IRM LLC 2011-04-13 CN disclosed
US-20110081365-A1 COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS IRM LLC (BM) 2011-04-07 US disclosed
US-20110081365-A1 COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS IRM LLC (BM) 2011-04-07 US disclosed
EP-2268618-A1 COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS IRM LLC (BM) 2011-01-05 EP disclosed
WO-2010144734-A1 BENZONAPHTHYRIDINE-CONTAINING VACCINES NOVARTIS AG (CH) 2010-12-16 WO disclosed
WO-2009111337-A1 COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS IRM LLC (BM) 2009-09-11 WO disclosed
WO-2009111337-A1 COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS IRM LLC (BM) 2009-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110081365-A1 COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS TLR5, TLR8, TLR7 KDM4E 1503/4885ALDH1A1 4772/4885MBOAT4 2557/4885
US-20240285611-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES BAX, BCL2, BCL3 KDM4E 2955/4885ALDH1A1 4319/4885MBOAT4 3854/4885
US-20230365526-A1 PYRIDAZINE DERIVATIVES FOR MODULATING NUCLEIC ACID SPLICING SNRPA, RBM17, SNRPB2 KDM4E 2629/4885ALDH1A1 3247/4885MBOAT4 4743/4885
US-11786519-B2 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases BAX, BCL2, BCL3 KDM4E 2955/4885ALDH1A1 4319/4885MBOAT4 3854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.